Efficacy and safety of Tandospirone combined with Atypical Antipsychotic drugs to Improve Cognitive function in Schizophrenia
With atypical antipsychotics for the control group, evaluate cognitive function in schizophrenia patients with antipsychotics combined 5-Hydroxytryptamine 1A (5-HT1A) receptor partial agonist tandospirone
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
100
Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.
Tandospirone,30mg per day
Guangzhou Psychiatric Hospital
Guangzhou, Guangdong, China
Measurement and treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery(MCCB) total score
Time frame: From baseline to 12 weeks of treatment
MATRICS Consensus Cognitive Battery(MCCB) factor score
Time frame: From baseline to 12 weeks of treatment
Positive and Negative Syndrome Scale(PANSS) total score
Time frame: From baseline to 12 weeks of treatment
Positive and Negative Syndrome Scale(PANSS) factor score
Time frame: From baseline to 12 weeks of treatment
Personal and Social Performance Scale(PSP) total score
Time frame: From baseline to 12 weeks of treatment
Clinical Global Impression(CGI) factor score
Time frame: From baseline to 12 weeks of treatment
Treatment Emergent Symptom Scale(TESS) factor score
Time frame: From baseline to 12 weeks of treatment
Functional magnetic resonance imaging(FMRI)
Time frame: From baseline to 12 weeks of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.